1 **The role of metal binding in the function of the human salivary antimicrobial peptide histatin-5**

2

3 Louisa Stewart^{1§}, YoungJin Hong^{1§}, Isabel Holmes¹, Samantha Firth¹, Jack Bolton¹, Yazmin Santos²,
4 Steven Cobb², Nicholas Jakubovics³, Karrera Djoko^{1*}

5

6 [§]These authors contributed equally to the experimental work. LS is listed first to acknowledge greater
7 involvement in manuscript preparation and editing.

8

9 ¹Department of Biosciences, Durham University, Durham DH1 3LE, United Kingdom

10 ²Department of Chemistry, Durham University, Durham DH1 3LE, United Kingdom

11 ³School of Dental Sciences, Newcastle University, Newcastle, United Kingdom.

12

13 *Corresponding author

14 karrera.djoko@durham.ac.uk

15

16 **Keywords:** antimicrobial peptide, histatin, copper, nutritional immunity, Streptococcus

17 **ABSTRACT**

18

19 Antimicrobial peptides (AMPs) are key components of diverse host innate immune systems.
 20 The family of human salivary AMPs known as histatins bind Zn and Cu. Fluctuations in Zn and Cu
 21 availability play significant roles in the host innate immune response (so-called “nutritional immunity”).
 22 Thus, we hypothesised that histatins contribute to nutritional immunity by influencing host Zn and/or
 23 Cu availability. We posited that histatins limit Zn availability (promote bacterial Zn starvation) and/or
 24 raise Cu availability (promote bacterial Cu poisoning). To test this hypothesis, we examined the
 25 interactions between histatin-5 (Hst5) and Group A *Streptococcus* (GAS), which colonises the human
 26 oropharynx. Our results showed that Hst5 does not strongly influence Zn availability. Hst5 did not
 27 induce expression of Zn-responsive genes in GAS, nor did it suppress growth of mutant strains that
 28 are impaired in Zn transport. Biochemical examination of purified peptides confirmed that Hst5 binds
 29 Zn only weakly. By contrast, Hst5 bound Cu tightly and it strongly influenced Cu availability. However,
 30 Hst5 did not promote Cu toxicity. Instead, Hst5 suppressed expression of Cu-inducible genes,
 31 stopped intracellular accumulation of Cu, and rescued growth of a $\Delta copA$ mutant strain that is
 32 impaired in Cu efflux. We thus proposed a new role for salivary histatins as major Cu buffers in saliva
 33 that contribute to microbial homeostasis in the oral cavity and oropharynx by reducing the potential
 34 negative effects of Cu exposure (e.g. from food) to microbes. Our results raise broad questions
 35 regarding the physiological roles of diverse metal-binding AMPs and the management of host metal
 36 availability during host-microbe interactions.

INTRODUCTION

Antimicrobial peptides (AMPs) are short, often cationic peptides that are secreted by diverse organisms from across the domains of life¹. These peptides usually act as immune effectors that kill invading microbes as part of the host innate immune system, but many also play key functions in the normal biology of the host organism. A sub-family of AMPs binds metals. These metallo-AMPs often synergise with metal ions or become activated upon metal binding²⁻⁴.

Salivary histatins comprise a family of His-rich, metallo-AMPs that are all derived from two parent peptides, namely Histatin-1 and Histatin-3^{5,6}. Both histatins are expressed constitutively by the salivary glands of humans and some higher primates^{6,7}. Upon secretion into the oral cavity, histatins are rapidly processed into shorter fragments^{8,9} by unidentified human salivary proteases or proteases from resident oral microbes. Of these fragments, Histatin-5 (Hst5; Table 1) is the best characterised.

Table 1. Hst5 peptides and variants used in this work.

Peptide	Sequence		
	1	11	21
Hst5	DS	HAKRHHGY	KRKFFHEKHHS HRGY
ΔH3	AS	AAKRHHGY	KRKFFHEKHHS HRGY
ΔH3,7	DS	AAKRHHGY	KRKFFHEKHHS HRGY
ΔH7,8	DS	HAKRAAGY	KRKFFHEKHHS HRGY
ΔH15,18,19	DS	HAKRHHGY	KRKFAEKAAAS HRGY

Hst5 is noted for its direct antimicrobial activity against the fungus *Candida albicans*^{10,11}. Unlike other AMPs, Hst5 does not appear to permeabilise fungal membranes, although it does destabilise some bacterial membranes¹¹. Beyond its direct action on membranes, the antimicrobial activity of Hst5 requires the peptide to be internalised into the cytoplasm, usually *via* energy-dependent pathways for peptide uptake^{11,12}. Once in the cytoplasm, Hst5 encounters its targets and causes toxicity *via* multiple pathways that are not fully elucidated^{10,13}.

Hst5 contains the characteristic Zn-binding motif His-Glu-x-His-His (Table 1), but whether Zn binding is essential for the antimicrobial activity of this AMP is unclear. Hst5 derivatives that lack one or all three His residues remain active against *C. albicans*¹⁴. Conflicting reports show that addition of Zn can both enhance¹⁵ and suppress¹⁶ Hst5 activity against this fungus. The reason for this discrepancy has not been identified. In addition, Hst5 possesses three Cu-binding motifs, namely the N-terminal ATCUN motif that binds Cu(II) and two *bis*-His motifs that bind one Cu(I) each (Table 1)¹⁷. Addition of Cu potentiates the activity of Hst5 against *C. albicans*¹⁷. This potentiation relies on the Cu(I) site but not the Cu(II) site¹⁷.

Beyond histatins and metallo-AMPs, metal-dependent host innate immune responses are well described. In response to microbial infection, metal levels and those of metal-binding or metal-transport proteins within a host organism can rise and fall, leading to fluctuations in metal availability within different niches in the infected host. Increases in metal availability promote microbial poisoning

while decreases in metal availability promote microbial starvation. These antagonistic host responses are known as “nutritional immunity”¹⁸. Do histatins and other metallo-AMPs contribute to these metal-dependent immune responses and, if so, how?

This study explored the relationship between Hst5 and metals, particularly Zn and Cu, and examined the role of this AMP in influencing metal availability during nutritional immunity. Based on the reported metal-dependent effects of Hst5 against *C. albicans* and on established features of nutritional immunity, we hypothesised that Hst5 either limits Zn availability (and promotes microbial Zn starvation) and/or raises Cu availability (and promotes Cu poisoning).

To test our hypothesis, the Gram-positive bacterium *Streptococcus pyogenes* (Group A *Streptococcus*, GAS) was used as a model. GAS colonises the human oropharynx, where it comes into contact with saliva and salivary components, but its interactions with Hst5 have not been described previously. Moreover, pathways for metal homeostasis in GAS are relatively well understood and phenotypes of mutant strains lacking key metal transport proteins are known¹⁹. These features enabled GAS to be exploited here as a tractable, well-defined experimental tool for examining the metal-dependent effects of Hst5.

RESULTS

Hst5 does not exert direct antibacterial effects against GAS or other oral streptococci.

The effects of Hst5 on growth of GAS were examined in a metal-deplete, chemically defined medium (CDM)²⁰. In this medium, up to 50 μ M Hst5 (ca. total histatin concentrations in fresh salivary secretions⁹) did not affect growth of wild-type GAS (Figure 1A). Identical results were obtained in THY medium (Figure S1A).

The effects of Hst5 on GAS survival were examined in 10 mM phosphate buffer^{11,15}. Under these conditions, up to 50 μ M Hst5 did not kill GAS (Figure 1B). Instead, Hst5 prolonged survival of this bacterium (Figure 1B). A parallel control experiment showed that the same concentrations of Hst5 killed *Pseudomonas aeruginosa* within minutes¹¹ (Figure S2A), confirming that our peptide stocks were active.

Figure 1. Effects of Hst5 on (A) growth and (B) survival of GAS. (A) Bacteria ($N = 2$) were cultured in CDM in the presence of Hst5 (0–50 μ M). **(B)** Bacteria ($N = 3$) were incubated in phosphate buffer (10 mM, pH 7.4; Pi), Na-Mops buffer (10 mM, pH 7.4; Mops), or artificial saliva salts (pH 7.2–7.4; Sal., see Dataset S1a for composition), with ($\circ$) or without ($\bullet$) Hst5 (50 μ M).

Like other cationic AMPs, the antimicrobial activity of Hst5 relies on initial electrostatic binding of the peptide to microbial surface proteins or membranes^{11,21}. Such interactions are suppressed by salts and high ionic strength buffers^{11,14,22-26}. To lower the ionic strength in our experiments, phosphate was replaced with Mops. Under these new conditions, Hst5 *did* kill GAS (Figure 1B). However, carryover salts from solutions used in preparing the inoculum abolished this killing effect (Figure S2B), underscoring the sensitivity of these assays to salt.

To better reflect the physiological context in which Hst5 plays a role, we repeated the kill assay in buffered “artificial saliva salts”, whose salt composition approximates healthy saliva (Dataset S1a). Hst5 did *not* kill GAS under these conditions (Figure 1B), confirming that the results in phosphate buffer are more physiologically relevant. For ease of comparison with existing literature, further experiments described below used phosphate buffer.

The lack of a direct antibacterial effect against GAS adds to the list of contradictory effects of Hst5 against streptococci reported in the literature²⁷⁻³². Given the sensitivity of these assays to the specific experimental conditions, the effects of Hst5 on GAS and five oral streptococci, namely *S. anginosus*, *S. mutans*, *S. oralis*, *S. salivarius*, and *S. sanguinis*, were examined here in parallel. Hst5 did *not* kill or inhibit growth of any of the streptococci under these conditions (Figure 2, Figure S1B). In fact, Hst5 promoted growth of *S. anginosus*, *S. oralis*, and, to a lesser extent, *S. sanguinis*. The mechanism behind this growth-promoting activity of Hst5 is beyond the scope of the present work, but is presumably related to the metal-chelating ability of this AMP (described below).

Figure 2. Effects of Hst5 on (A) growth and (B) survival of oral streptococci. Bacteria ($N = 2$) were cultured in CDM (A) or incubated in phosphate buffer (B), with (○) or without (●) Hst5 (50 μ M).

Hst5 does not strongly influence Zn availability.

To determine whether Hst5 contributes to nutritional immunity, the effects of this AMP on GAS were re-examined in the presence of up to 50 μM Zn (equimolar with Hst5 and in excess of Zn concentrations in whole saliva³³). Zn neither suppressed nor enhanced the direct effects of Hst5 on GAS (Figure 3, Figure S1C), suggesting that Hst5 promotes neither Zn starvation nor poisoning, respectively.

Figure 3. Effects of Zn on (A) survival and (B) growth of GAS in the presence of Hst5. Bacteria ($N = 3$) were incubated in phosphate buffer (A) or cultured in CDM (B), in the presence of Zn (0–50 μM), with ($\circ$) or without ($\bullet$) Hst5 (50 μM).

Zn starvation or poisoning may not strongly affect wild-type GAS since the transcriptionally-responsive system for Zn homeostasis responds to, and thus counters, such perturbations in Zn availability (Figure 4). This transcriptional response, *i.e.* expression of the three Zn-responsive genes *adcA*, *adcAII*, and *czcD* (Figure 4), was examined here. Only bacteria grown in CDM were used for analyses, since poor RNA yields were obtained from bacteria that were incubated in phosphate buffer, likely associated with the progressive loss of viability under these conditions (*cf.* Figure 1B).

In the control experiment, adding Zn alone did not further repress transcription of *adcA* and *adcAII*, but it did induce expression of *czcD* (Figure S3A), consistent with an increase in Zn availability. Conversely, adding the Zn chelator TPEN did not affect transcription of *czcD*, but it did induce expression of *adcA* and *adcAII*, consistent with a decrease in Zn availability (Figure S3B). By contrast, adding Hst5 alone perturbed neither the basal expression of *adcA* or *adcAII* (Figure 5A), nor the Zn-dependent expression of *czcD* (Figure 5B).

Figure 4. Metal homeostasis in GAS and hypothesised actions of Hst5. **Zn uptake:** AdcAI and AdcAII capture extracellular Zn and transfer this metal to AdcBC for import into the cytoplasm. These proteins are transcriptionally upregulated by AdcR in response to decreases in Zn availability³⁴. **Zn efflux:** CzcD exports excess Zn out of the cytoplasm. It is transcriptionally upregulated by GcZA in response to increases in Zn availability³⁵. **Cu efflux:** CopA exports excess Cu out of the cytoplasm. It is transcriptionally upregulated by CopY in response to increases in Cu availability³⁶. **Hypothesised actions of Hst5:** Hst5 may remain extracellular, bind Zn or Cu, and suppress extracellular metal availability. Alternatively, Hst5 may become internalised and suppress intracellular metal availability. Hst5 may also become internalised as the Zn-Hst5 or Cu-Hst5 complex, facilitate entry of Zn or Cu into the cytoplasm, and increase metal availability.

As described earlier, Zn uptake by AdcAI and Zn efflux by CzcD may mask the effects of Hst5 on Zn availability (Figure 4). Thus, the effects of Hst5 were examined further using the $\Delta adcAI$ and $\Delta czcD$ mutant strains. Although additional Zn-binding lipoproteins such as AdcAII contribute to Zn acquisition³⁷, AdcAI is thought to act as the primary Zn importer^{37,38}. Therefore, only the $\Delta adcAI$ mutant was employed here. The control experiment confirmed that the $\Delta adcAI$ and $\Delta czcD$ mutant strains were sensitive to growth inhibition by TPEN^{37,38} and added Zn^{35,38}, respectively (Figure S4).

The $\Delta adcAI$ mutant strain displayed wild-type growth and survival phenotypes in the presence of Hst5 (Figures 5B–C), strengthening the proposal that Hst5 does not starve GAS of nutrient Zn.

Likewise, the $\Delta czcD$ mutant strain displayed wild-type survival phenotype (Figure 5E). Interestingly, Hst5 weakly improved (instead of further inhibited) growth of the $\Delta czcD$ mutant in the presence of 10 μ M of added Zn (Figure 5F). This growth-promoting effect became apparent only upon comparing final culture densities (Figure 5G), since exponential growth rates remained unchanged (Figure 5H). It appeared to require the predicted Zn-binding ligands His15, His18, and His19^{39,40}, since growth of the Zn-treated $\Delta czcD$ mutant in the presence of the $\Delta H15,18,19$ variant of Hst5 was indistinguishable with growth in the absence of Hst5 (Figure S5A–B). The roles of the other His residues were less clear (Figure S5A–B). Nevertheless, it can be concluded that Hst5 suppresses (instead of potentiates) Zn toxicity to GAS.

Figure 5. Effects of Hst5 on Zn availability. (A) Expression of Zn-responsive genes. Bacteria ($N = 7$) were cultured in CDM with ($\circ$) or without ($\bullet$) Hst5 (50 μ M). Levels of *adcAI*, *adcAII*, and *czcD* mRNA were determined by qRT-PCR and normalised to *holB*. (B) Zn-dependent expression of *czcD*. Bacteria ($N = 3$) were cultured in CDM with or without added Zn (2 or 5 μ M), with ($\circ$) or without ($\bullet$) Hst5 (50 μ M). Levels of *czcD* mRNA were measured by qRT-PCR, normalised to *holB*, and compared to normalised mRNA levels of the corresponding untreated controls (0 μ M added Zn). (C) Growth of $\Delta adcAI$. Bacteria ($N = 3$) were cultured in CDM with or without Hst5 (0 or 50 μ M). (D) Survival of $\Delta adcAI$. Bacteria ($N = 2$) were incubated in phosphate buffer with ($\circ$) or without ($\bullet$) Hst5 (50 μ M). (E) Survival of $\Delta czcD$. Bacteria ($N = 2$) were incubated in phosphate buffer with or without added Zn (50 μ M), with ($\circ$) or without ($\bullet$) Hst5 (50 μ M). (F) Growth of $\Delta czcD$. Bacteria ($N = 3$) were cultured in CDM in the presence of Zn (0–20 μ M), with ($\circ$) or without ($\bullet$) Hst5 (50 μ M). (G) Final culture densities from panel F. (H) Exponential growth rates from panel F. (I) Intracellular Zn

levels in $\Delta czcD$. Bacteria ($N = 3$) were cultured in CDM in the presence of Zn (0–5 μM), with or without Hst5 (50 μM). Intracellular levels of Zn were measured by ICP MS and normalised to colony counts.

Two mechanisms are immediately plausible (*cf.* Figure 4): (i) Hst5 binds extracellular Zn and weakly suppresses entry and accumulation of this metal ion into the cytoplasm, leading to less Zn toxicity, or (ii) Hst5 binds intracellular Zn and enables more Zn to accumulate in the cytoplasm, but with less toxicity. To distinguish these models, total intracellular Zn levels in the $\Delta czcD$ mutant strain were assessed by ICP MS. Only up to 5 μM Zn was used, since adding 10 μM Zn did not produce sufficient biomass for metal analyses. Only wild-type Hst5 was used, owing to the large culture volumes required and the high cost of peptide synthesis.

Figure 5I shows that growth in the presence of added Zn increased intracellular Zn levels in the $\Delta czcD$ mutant, but co-treatment with Hst5 suppressed this effect. These results initially appeared to support the first model, in which Hst5 binds extracellular Zn. However, intracellular Cu levels in these samples were similarly elevated in the absence of Hst5, and similarly suppressed in the presence of Hst5 (Figure S5C). At this stage, we cannot exclude the possibility that Zn treatment led to spurious effects associated with the observed growth defect. Thus, while our data hint at a role for Hst5 in weakly influencing extracellular Zn availability to GAS, they are not conclusive, particularly when compared with the clear role of Hst5 in strongly influencing Cu availability (described below).

Hst5 binds extracellular Cu(II) and strongly limits Cu availability.

Like Zn, adding up to 50 μM of Cu (equimolar with Hst5; *ca.* 10X higher than Cu concentrations in saliva⁴¹⁻⁴³) did not directly affect the growth or survival phenotype of wild-type GAS in the presence of Hst5 (Figure 6, Figure S1D). However, as in the case with Zn, any effect of Hst5 on Cu availability may not directly affect wild-type GAS as a result of the transcriptionally-responsive system for Cu export (Figure 4). This transcriptional response was hereby examined to probe the Cu-linked action of Hst5.

Figure 6. Effects of Cu on (A) survival and (B) growth of GAS in the presence of Hst5. (A)

Bacteria ($N = 5$) were incubated in phosphate buffer (A) or cultured in CDM glucose (B), with or without added Cu (50 μM), with (○) or without (●) Hst5 (50 μM).

The control experiment showed that adding the extracellular Cu chelator BCS did not further repress expression of *copA* and *copZ* (Figure S3C), suggesting that GAS grown in CDM was Cu-deplete. Adding Cu to the culture medium induced expression of both genes (Figure S3D, Figure 7A), consistent with an increase in Cu availability²⁰. Intriguingly, co-treatment with Hst5 suppressed (instead of enhanced) this Cu-dependent induction (Figure 7A). This effect required the predicted Cu(II) binding site^{17,44}, since the Δ H3 and Δ H3,7 variants lacking His3 (Table 1) were less effective at reducing expression of *copA* and *copZ* (Figure 7B). By contrast, it did not require the predicted Cu(II) binding sites¹⁷, since the effects of the Δ H7,8 and Δ H15,18,19 variants lacking either of the *bis*-His motifs (Table 1) were indistinguishable to that of the wild-type peptide (Figure 7B).

Figure 7. Effects of Hst5 on Cu availability. (A) Expression of Cu-inducible genes. Bacteria ($N = 3$) were cultured in CDM with or without added Cu (10 μ M), with or without Hst5 (50 μ M). Levels of *copA* and *copZ* mRNA were measured by qRT-PCR, normalised to *ho1B*, and compared with normalised mRNA levels of the corresponding untreated controls (0 μ M Cu). (B) Effects of Hst5 variants on expression of Cu-inducible genes. The experiment was performed as described in panel A. The following treatments suppressed Cu-dependent *copA* expression when compared with untreated control: Hst5 ($***P = 0.0003$), Δ H7,8 ($***P = 0.0003$), Δ H15,18,19 ($**P = 0.0018$). The

following treatments had no effect: $\Delta H3$ ($P = 0.1$), $\Delta H3,7$ ($P = 0.2$). The following treatments suppressed Cu-dependent *copZ* expression when compared with untreated control: Hst5 ($***P = 0.001$), $\Delta H7,8$ ($***P = 0.001$), $\Delta H15,18,19$ ($**P = 0.003$). The following treatments had no effect: $\Delta H3$ ($P = 0.7$), $\Delta H3,7$ ($P = 0.1$). **(C) Survival of $\Delta copA$.** Bacteria ($N = 2$) were incubated in phosphate buffer with or without added Cu (50 μM), with ($\circ$) or without ($\bullet$) Hst5 (50 μM). **(D) Growth of $\Delta copA$.** Bacteria ($N = 3$) were cultured in CDM in the presence of added Cu (0–20 μM), with or without Hst5 (50 μM). **(E) Effects of Hst5 variants on growth of $\Delta copA$.** Bacteria ($N = 3$) were cultured in CDM with or without added Cu (20 μM), with or without Hst5 or its variants (50 μM). Complete growth curves are shown in Figure S6. For ease of comparison, only OD_{600} values from the end of the experiment ($t = 10$ h) were plotted here. **(F) Intracellular Cu levels in $\Delta copA$.** Bacteria ($N = 3$) were cultured in CDM in the presence of Cu (0–10 μM), with or without Hst5 (50 μM). Intracellular levels of Cu were measured by ICP MS and normalised to colony counts.

Further examination using a Cu-sensitive $\Delta copA$ mutant strain that lacks the Cu-effluxing P-type ATPase²⁰ (Figure 4) revealed no difference between the survival phenotype of this mutant strain and that of the wild-type in the presence of Hst5 (Figure 7C). There was, however, a clear difference in their growth phenotypes. Co-treatment with Hst5 rescued growth of the $\Delta copA$ mutant strain in the presence of added Cu (Figure 7D). This protective effect again required the His3 ligand for Cu(II), but neither of the two *bis*-His ligands for Cu(I) (Figure 7E, Figure S6A). These results indicate that Hst5 acts as a Cu(II)-specific peptide.

Two mechanisms are again plausible (Figure 4): (i) Hst5 binds extracellular Cu and suppresses entry of Cu into the GAS cytoplasm, leading to less Cu toxicity, or (ii) Hst5 binds intracellular Cu, allowing intracellular Cu levels to rise without significant toxicity. The latter would resemble the model described for GSH in binding (buffering) excess intracellular Cu²⁰. Since Cu(II) is not thought to exist within the reducing cytoplasm, the first model is more likely. Consistent with this proposal, ICP MS analyses of total metal levels in the $\Delta copA$ mutant confirmed that growth in the presence of Cu led to an increase in total intracellular Cu levels, but co-treatment with Hst5 strongly suppressed these levels (Figure 7F). Unlike the situation described earlier for the $\Delta czcD$ mutant, there were no unanticipated effects on other metal levels such as Zn (Figure S6B). Thus, it can be concluded that Hst5 binds extracellular Cu(II) and strongly limits (instead of promotes) Cu availability to GAS.

Molecular basis for the action of Hst5 in weakly influencing Zn availability.

Hst5 is thought to bind up to three Zn atoms. ITC measurements yielded log K_{Zn} values of 4.0, 5.0, and 5.1⁴⁴. In agreement with Zn binding weakly to Hst5, the Zn-Hst5 complex dissociated upon passage through a desalting column (Figure 8A).

The affinities of Hst5 to Zn were re-examined here by equilibrium competition with the colorimetric Zn indicator Zincon (log $K_{Zn} \sim 6.0$) and monitoring solution absorbances of *apo*-Zincon and Zn-Zincon at 466 nm and 620 nm, respectively (Figure 8B). Unexpectedly, the competition curve (in the presence of Hst5) was nearly indistinguishable from the control (in the absence of Hst5)

(Figure 8C). Moreover, a new peak at 650 nm appeared in the presence of Hst5 (Figure 8B), indicating formation of a new species, likely a ternary complex between Hst5, Zincon, and Zn. This peak did not completely disappear upon adding excess Hst5 (Figure 8B). These results indicate that Hst5 does not compete effectively with Zincon, and that this peptide binds Zn more weakly than previously estimated by ITC⁴⁴.

Figure 8. Zn affinity of Hst5. (A) Representative separation of Hst5 (○) and Zn (●) on a polyacrylamide desalting column. (B) Representative spectral changes upon addition of Zn (0–50 μM) into apo-Zincon (20 μM): (i) in the absence (solid traces) or (ii) presence (dashed traces) of Hst5 (20 μM). (iii) Overlaid spectra for 0 and 50 μM Zn from panels (i) and (ii). (iv) Representative spectral changes upon addition of excess Hst5 (0–200 μM) into a solution of Zn (20 μM) and apo-Zincon (25 μM). (C) Representative normalised plot of the absorbance intensities of apo-Zincon at 467 nm upon addition of Zn in the absence (●) or presence (○) of Hst5 (20 μM).

A previous study showed effective competition between Hst5 and Zincon in phosphate buffer, with Hst5 removing 2 molar equiv. of Zn from Zincon¹⁵. However, when used at millimolar concentrations, phosphate can compete for binding Zn ($\log K_{Zn} \sim 2.4$)⁴⁵. Repeating the control titration in phosphate buffer (50 mM) instead of Mops led to clear partitioning of Zn between Zincon and the buffer (Figure S7A-B). Prolonged incubation (>10 min) of Zn-Zincon in this buffer led to loss of the characteristic blue colour (Figure S7C). For these reasons, estimates of Zn affinity and stoichiometry of Hst5 using Zincon in Mops buffer are likely to be more reliable.

The weak binding of extracellular Zn to Hst5 was clearly insufficient to starve wild-type GAS of nutrient Zn (*cf.* Figures 5A, 5C), indicating that this peptide does not compete with the high-affinity, Zn-specific uptake protein AdcAI (*cf.* Figure 4). Therefore, the Zn affinities of AdcAI were examined here by competition with the colorimetric Zn indicator Mag-fura2 (Mf2). The competition curve, generated by monitoring the solution absorbance of apo-Mf2 at 377 nm, clearly showed two Zn binding sites in AdcAI (Figure 9A) as anticipated⁴⁶. The tight site outcompeted Mf2, as evidenced by

the lack of Representative spectral changes upon adding up to 1 molar equiv. of Zn vs. AdcAI (Figure 9A). The weak site competed effectively with Mf2 with a $\log K_{\text{ZN}} = 8.5 (\pm 0.2)$. The affinity of the tight site was better estimated using Quin-2 (Q2) as the competitor. By monitoring absorbance of *apo*-Q2 at 266 nm, a $\log K_{\text{ZN}} = 12.5 (\pm 0.2)$ was obtained for this site (Figure 9B).

Figure 9. Zn affinity of AdcAI. (A) Weak site. (i) Representative spectral changes upon titration of Zn (0–25 μM) into a mixture of *apo*-Mf2 (10 μM) and AdcAI (5 μM). **(ii)** Normalised plot of the absorbance intensities of *apo*-MF2 (10 μM) at 377 nm upon addition of Zn in the absence (●) or presence (○) of AdcAI (5 μM). Competition with Hst5 (□; 10 μM) is shown for comparison. **(B) Tight site. (i)** Observed Representative spectral changes upon titration of Zn (0–25 μM) into a mixture of *apo*-Q2 (7.5 μM) and AdcAI (10 μM). **(ii)** Normalised plot of the absorbance intensities of *apo*-Q2 (7.5 μM) at 262 nm upon addition of Zn in the absence (●) or presence (○) of AdcAI (10 μM).

The $\log K_{\text{Zn}}$ values determined here were each ca. 1000-fold tighter than those determined previously by ITC⁴⁶. ITC can underestimate metal binding affinities due to lack of sensitivity, lack of specificity, and potential side reactions (e.g. competition with buffers)⁴⁷. Crucially, Hst5 did not compete with Mf2 for Zn (Figure 9A). These *relative* affinities, determined using the *same* approach under the *same* conditions, support the hypothesis that Hst5 does not compete with AdcAI for binding Zn, and provide a molecular explanation for why this AMP does not limit the availability of extracellular nutrient Zn to wild-type GAS.

Hst5 did not affect growth of GAS even when AdcAI was deleted by mutagenesis (*cf.* Figure 5D), suggesting that this peptide does not compete with other high-affinity Zn uptake proteins such as AdcAII (*cf.* Figure 4). AdcAII was expressed here for metal competition assays. However, consistent with a previous report⁴⁸, it co-purified with 1 molar equiv. of bound Zn, which could not be removed without denaturing the protein. Nevertheless, the reported affinity of the *S. pneumoniae* homologue ($\log K_{\text{ZN}} = 7.7$; 67% identity, 81% similarity), determined *via* competition with Mf2⁴⁹, is consistent with our proposal that Hst5 does not compete effectively with AdcAII for binding Zn.

Molecular basis for the action of Hst5 in strongly influencing Cu availability.

Hst5 binds one Cu(II) ion with $\log K_{Cu} = 11.1$, as determined previously by competition with NTA¹⁷. Since both Hst5 and NTA have weak optical signals (Figure S8), this $\log K_{Cu}$ value was re-evaluated here using PAR as an intensely coloured mediator⁵⁰ between NTA and Hst5. The control titration confirmed that adding Cu(II) decreased the solution absorbance of apo-PAR at 400 nm and concomitantly increased that of the Cu(II)-PAR complex⁵¹ at 512 nm (Figure 10A, Figure S9A). PAR was then competed with 20 molar equiv. of NTA and, separately, Hst5 (Figures 10B-C). This PAR-mediated competition with NTA yielded a $\log K_{Cu} = 12.1 (\pm 0.1)$ for Hst5 (Figure 10C, Figure S9B-C), *i.e.* ~10-fold tighter than estimates from the direct competition with NTA¹⁷. As previously acknowledged, the weak solution absorbances of Cu^{II}-NTA and Cu^{II}-Hst5 complexes did not saturate even in the presence of excess Cu (Figure S8B), indicating potential Cu-buffer interactions that were not accounted in the calculations, which may explain the slight underestimate in the literature^{17,52}.

Figure 10. Cu(II) affinity of Hst5. (A) Representative spectral changes upon titration of Cu(II) (0–160 μM) into apo-PAR (20 μM). (B) Normalised plot of the absorbance intensities of CuPAR at 512 nm upon titration of Cu into apo-PAR (20 μM) in the absence (●) or presence (○) of NTA (400 μM). (C) Normalised plot of the absorbance intensities of CuPAR at 512 nm upon titration of Cu into apo-PAR (10 μM) in the absence or presence of Hst5 peptides (200 μM).

Consistent with an earlier report¹⁷, deletion of either *bis*-His motif did not affect the competition between Hst5 and PAR (Figure 10C), confirming that these residues do not participate in binding Cu(II). By contrast, deletion of His3 abolished the competition with PAR (Figure 10C), confirming the ATCUN motif as Cu(II)-binding ligands. More precise affinities for these variants were obtained *via* competition with the fluorometric Cu(II) chelator DP2⁵³. By monitoring quenching of apo-DP2 fluorescence at 550 nm, $\log K_{Cu}$ values of 9.3 (± 1.0) and 9.4 (± 0.8) were obtained for the ΔH3 and ΔH3,H7 variants, respectively (Figure S9D). These values indicate that loss of the ATCUN His weakened the affinity of Hst5 to Cu(II) by ~100-fold.

DISCUSSION

The role of metal binding in histatin activity: a framework for other metallo-AMPs.

Our work establishes that Hst5 does not contribute to nutritional immunity against GAS, since this AMP does starve this bacterium of nutrient Zn, nor does it enhance Zn or Cu toxicity. These findings are consistent with the results from a genome-wide screen of a GAS mutant library, which did not identify Zn uptake, Zn efflux, or Cu efflux genes as essential for growth in saliva⁵⁴.

The low affinity of Hst5 to Zn, particularly when compared with the high affinities of the Zn uptake lipoproteins AdcAI and AdcAII, explains why Hst5 does not starve GAS of *nutrient* Zn. Here, the antimicrobial protein calprotectin provides a useful comparison. Calprotectin binds two Zn ions with affinities ($\log K_{Zn} > 11$ and > 9.6)⁵⁵ that are comparable to those of AdcAI and tighter than that of AdcAII. Indeed, adding calprotectin induces a robust Zn starvation response in streptococci^{56,57}, consistent with its established role in nutritional immunity.

Its low affinity to Zn also explains why Hst5 only weakly influences availability of excess (*toxic*) Zn to GAS. Like most culture media, our growth medium²⁰ contains phosphate (~6 mM) and amino acids (~6 mM total), which would outcompete Hst5 (50 μ M) for binding Zn⁴⁵. For these reasons, synergistic effects between Zn and Hst5, such as those observed *in vitro* against *C. albicans*, may not result from a direct binding of Zn to Hst5. Instead, the separate biological effects of Zn and Hst5 may need to be considered. For instance, Zn and Hst5 may act on the same cellular targets or pathways. Alternatively, growth and survival of cells in the presence of Hst5 may require certain proteins that become poisoned in the presence of Zn (or *vice versa*).

If competing ligands become depleted, for example as a result of bacterial growth, then Hst5 can become competitive and bind Zn, particularly when Zn concentrations are high. Such shifts in Zn speciation likely explain why the protective effect of Hst5 on the GAS $\Delta czcD$ mutant during conditions of Zn stress became apparent only at the later stages of growth (*cf.* Figures 5F-G). The increased binding of Zn to Hst5 may at this point suppress non-specific Zn import into the GAS cytoplasm, for instance by outcompeting promiscuous divalent metal transporters or by suppressing direct Zn diffusion across the lipid bilayer.

Saliva contains ~10 mM phosphate^{58,59} and proteinaceous components that may also bind Zn⁶⁰. Unlike *in vitro* growth media, saliva and its components are continuously refreshed *in vivo*. Therefore, Hst5 is unlikely to strongly influence Zn speciation and availability in saliva. *In vivo*, synergistic effects between Zn and Hst5 may nonetheless occur, but likely *via* mechanisms that do not rely on formation of a Zn-Hst5 complex.

By contrast to Zn, the high affinity of Hst5 to Cu(II) explains why this AMP strongly influences Cu availability to GAS (*cf.* Figure 7) and, presumably, other microbes. Hst5 outcompetes background competing ligands that may also bind Cu, such as phosphate ($\log K_{Cu} \sim 3.3$)⁶¹ and amino acids. In addition, Hst5 likely outcompetes transporters that catalyse *non-specific* Cu(II) uptake into GAS. This model will need to be tested by directly competing Hst5 and these transporters *in vitro*, but the latter are yet to be identified and are likely to be diverse.

Does Hst5 suppress *nutrient* Cu availability and cause Cu starvation? The GAS genome does

not encode Cu-dependent proteins or enzymes, and so this bacterium is not thought to use or uptake nutrient Cu. Therefore, this proposal will need to be tested using other microbes that do need nutrient Cu. Nevertheless, parallels can again be drawn with calprotectin, which binds two Cu(II) ions with affinities ($\log K_{\text{Cu}} = 11.4$ and 12.7)⁶² that are comparable to that of Hst5. Treatment with calprotectin induces a Cu starvation response in *C. albicans*⁶², suggesting that Hst5 may also elicit microbial Cu starvation response. Yet, Hst5 activity against this fungus appears linked to Cu excess and not Cu starvation¹⁷. Thus, the potential role of Hst5 in limiting nutrient Cu awaits further clarification.

The approaches described here can help define the role of metal binding in the function of metallo-AMPs in general. As an illustration, microplusin, a Cu-binding AMP from cattle ticks, is thought to withhold nutrient Cu from *Cryptococcus neoformans*^{63,64}. This proposal was based on the observation that supplemental Cu suppressed the antimicrobial activity of this AMP. By measuring expression of Cu-responsive genes and total intracellular Cu levels in *C. neoformans*, one can determine whether microplusin binds Cu outside or inside target cells, and whether microplusin indeed influences Cu availability to these cells. By measuring the Cu affinity of microplusin and comparing it to those of key Cu uptake transporters in *C. neoformans* such as Ctr1, one can further determine whether microplusin is likely to bind Cu in the relevant host fluid, or whether the synergy between this AMP and Cu is associated with other unidentified mechanisms.

Metal binding by histatins: implications for bacterial colonisation in the oral cavity and oropharynx.

GAS causes >600 million worldwide cases of pharyngitis each year⁶⁵, although asymptomatic carriage in the oropharynx is common, especially among children⁶⁶. This host niche is rich in saliva, and the interactions between GAS and components of this host fluid are key for colonisation, infection, and subsequent transmission of this bacterium⁶⁷⁻⁶⁹. For example, exposure to saliva promotes aggregation of GAS and blocks adherence to mucosal epithelia⁷⁰. However, GAS produces surface adhesins that aid in binding to host mucosal surfaces⁷¹. Saliva also contains polysaccharides and glycoproteins that may serve as sources of nutrients. Accordingly, carbohydrate utilisation genes in GAS are highly expressed upon exposure to saliva⁷², and mutant strains lacking these genes show decreased fitness in saliva⁵⁴. Given the widely reported antimicrobial activity of Hst5, salivary histatins are thought to act as antimicrobial peptides. Yet, our work shows that Hst5 does not kill or inhibit growth of GAS under saliva-relevant conditions.

Discussions surrounding histatins have thus far focused on the *antagonistic* relationship between these AMPs and opportunistic oral pathogens *in vivo*. By comparison, little is known about the potentially *harmonious* relationship between histatins and microbes that normally colonise healthy oral and oropharyngeal tissues. We showed here that Hst5 does not kill oral streptococci, which represent the most abundant microbial taxon in healthy human oral cavity⁷³⁻⁷⁶ and oropharynx⁷⁷. This lack of an anti-streptococcal effect contrasts with the potent antibacterial effects of Hst5 against ESKAPE pathogens¹¹, although the latter are worth revisiting, to verify that they are not associated with artificial experimental conditions that do not mimic the saliva.

While total levels of intact, full-length Hst5 and major histatins in fresh salivary gland

secretions are high (up to 50 μM)⁹, steady-state levels in whole saliva are low⁹ as a consequence of peptide degradation by unidentified salivary proteases and proteases from resident oral microbes^{78,79}. Nearly fifty histatin-derived peptide fragments have been identified^{80,81}. Many are associated with reduced antimicrobial activities^{8,80}, raising the question whether an antimicrobial role is the major physiological role for the histatins.

Intriguingly, proteolytic cleavage of histatins in saliva typically leads to retention of the original Cu(II)-binding ATCUN motif (DSH-) and simultaneous generation of new ATCUN motifs as byproducts (RHH-, EKH-, KFH-, KRH-, KHH-, HSH-)⁸⁰. These diverse new motifs likely continue to bind Cu(II)⁸², raising the intriguing possibility that Cu binding is the key physiological role for histatins.

We speculate that histatins contribute to oral and oropharyngeal health by buffering Cu availability. Steady-state levels of Cu in healthy saliva are sub-stoichiometric relative to histatins⁴¹⁻⁴³, but additional Cu does enter the oral cavity through food (e.g. liver, shellfish, dark chocolate). In addition, Cu levels in saliva can also rise during periodontal diseases⁸³⁻⁸⁵. By buffering Cu, histatins may protect resident oral microbes from the potential toxic effects of a sudden or sustained exposure to excess Cu, and thus promote microbial homeostasis in saliva-rich host niches.

Streptococci do not use nutrient Cu, and so these bacteria will only benefit from the action of histatins as Cu-buffering agents. This idea is not inconsistent with the relative dominance of *Streptococcus* species in the human oral cavity^{74,75} and oropharynx⁷⁷. However, other resident oral microbes, such as commensal *Neisseria* species and even *C. albicans*, need nutrient Cu for respiration and energy production. Do histatins buffer *nutrient* Cu availability to these microbes? The oral cavity and oropharynx are also major entry points for pathogens that can cause oral, gut, and respiratory infections, many of which also need nutrient Cu. How is Cu availability managed, such that toxicity is limited to resident microbes but enhanced to foreign, potentially pathogenic microbes, and that nutrient supply is maintained to resident microbes but suppressed to pathogenic ones? Are there species-specific differences? What is the molecular basis of such differences? These studies are ongoing in our laboratory.

METHODS

Data presentation. Except growth curves, individual replicates from microbiological experiments are plotted, with shaded columns representing the means and error bars representing standard deviations. Growth curves show the means, with shaded regions representing standard deviations. The number of biological replicates (independent experiments using different starter cultures and performed on different days; *N*) is stated in figure legends. Statistical analyses have been performed on all data but notations of statistical significance are displayed on graphical plots only if they aid in rapid, visual interpretation. Unless otherwise stated, statistical tests used two-way analysis of variance using the statistical package in GraphPad Prism 8.0. All analyses were corrected for multiple comparisons. In the case of metal-protein and metal-peptide titrations, individual data points from two technical replicates (independent experiments performed on different days but using the same protein or peptide preparation) are plotted, but only representative spectra are shown for clarity of presentation.

Reagents. Sulfate and chloride salts of metals were used interchangeably. Peptides were synthesised commercially as the acetate salt, purified to >95% (GenScript), and confirmed to be metal-free by ICP MS. Concentrations of stock peptide solutions were estimated using solution absorbances at 280 nm in Mops buffer (50 mM, pH 7.4; $\epsilon_{280} = 2667 \text{ cm}^{-1}$). Concentrations of fluorometric and colourimetric metal indicators (Zincon, PAR, Magfura-2, Quin-2, BCS, DP-2) were standardised using a commercial standard solution of copper chloride. Concentrations of optically silent chelators (NTA) were standardised by competition with a standardised solution of Zn-Zincon.

Strains and culture conditions. Bacterial strains are listed in Dataset S1b. All bacterial strains (Dataset S1b) were propagated from frozen glycerol stocks onto solid THY (Todd Hewitt + 0.2% yeast extract) medium without any antibiotics. Liquid cultures were prepared in THY or CDM-glucose²⁰. All solid and liquid growth media contained catalase (50 $\mu\text{g/ml}$).

Survival assays. Fresh colonies from an overnight THY agar were resuspended to 10^6 - 10^7 CFU/mL in either potassium phosphate buffer (10 mM, pH 7.4), Mops buffer (10 mM, pH 7.4), or artificial salivary salts (pH 7.2; Dataset S1a). The cultures were incubated at 37 °C with or without Hst5 and/or metals as required. At $t = 0, 1, \text{ and } 3 \text{ h}$, cultures were sampled and serially diluted in CDM-glucose. Exactly 10 μL of each serial dilution was spotted onto fresh THY agar. Colonies were enumerated after overnight incubation at 37 °C.

Growth assays. Colonies from an overnight THY agar were resuspended in CDM-glucose to an $\text{OD}_{600} = 0.01$. Growth was assessed at 37 °C in flat-bottomed 96-well plates (200 μL per well) using an automated microplate shaker and reader. Each plate was sealed with a gas permeable, optically clear membrane (Diversified Biotech). OD_{600} values were measured every 20 min for 10 h. The plates were shaken immediately before each reading (200 rpm, 1 min, double orbital mode). OD_{600} values were not corrected for path length (ca. 0.58 cm for a 200- μL culture).

RNA extraction. Colonies from an overnight THY agar were resuspended in CDM-glucose to an $\text{OD}_{600} = 0.01$ and incubated in 24-well plates (1.6 mL per well) without shaking at 37 °C. Each plate was sealed with a gas permeable, optically clear membrane (Diversified Biotech). At $t = 4 \text{ h}$, cultures were centrifuged (4,000 $\times g$, 4°C, 5 min) and bacterial pellets were resuspended immediately in RNAPro Solution (0.5 mL; MP Biomedicals). Bacteria were lysed in Lysing Matrix B and total RNA was extracted following manufacturer's protocol (MP Biomedicals). Crude RNA extracts were treated with RNase-Free DNase I (New England Biolabs). Complete removal of gDNA was confirmed by PCR using gapA-check-F/R primers (Dataset S1c). gDNA-free RNA was purified using Monarch RNA Clean-up Kit (New England Biolabs) and visualised on an agarose gel.

qRT-PCR analyses. cDNA was generated from RNA (1.6 μg) using SuperScript® IV First-Strand Synthesis System (Invitrogen). Each qRT-PCR reaction (20 μL) contained cDNA (5 ng) as template and the appropriate primer pairs (0.4 μM ; Dataset S1c). Samples were analysed in technical duplicates. Amplicons were detected with Luna® Universal qRT-PCR Master Mix (New England Biolabs) in a CFXConnect Real-Time PCR Instrument (Bio-Rad Laboratories). C_q values were calculated using LinRegPCR⁸⁶ after correcting for amplicon efficiency. C_q values of technical duplicates were typically within ± 0.25 of each other. *hoI/B*, which encodes DNA polymerase III, was used as reference gene. Its transcription levels remained constant in all of the experimental conditions

tested here.

Intracellular metal content. Colonies from an overnight THY agar were resuspended in CDM-glucose to an $OD_{600} = 0.02$ and incubated at 37 °C with or without Hst5 and/or metals as required. At $t = 4$ h, an aliquot was collected for the measurement of plating efficiency (colony counts). The remaining cultures were harvested (5,000 g, 4 °C, 10 min), and washed once with ice-cold wash buffer (1 M *D*-sorbitol, 50 mM Tris-HCl, 10 mM $MgCl_2$, 1 mM EDTA, pH 7.4) and twice with ice-cold PBS. The final pellets were dissolved in concentrated nitric acid (100 μ L), heated (85 °C, 1.5 h), and diluted to 3.5 mL with 2 % nitric acid. Total metal levels were determined by ICP MS. The results were normalised to colony counts.

Elution of Zn-Hst5 on a desalting column. Apo-Hst5 (100 μ M) was incubated with 1.5 molar equiv. of Zn for 15 min at the bench and loaded onto a polyacrylamide desalting column (1.8 kDa molecular weight cutoff, Thermo Scientific). Peptide content in each fraction was verified using QuantiPro BCA Assay Kit (Merck). Zn content was determined using PAR against a standard curve.

Equilibrium competition reactions. Our approach to determine metal-binding affinities followed that described by Young and Xiao⁴⁷. For each competition (eq 1 below), a master stock was prepared to contain both competing ligands (L1 and L2) in Mops buffer (50 mM, pH 7.4). Serial dilutions of the metal (M) were prepared separately in deionised water. Exactly 135 μ L of the master stock was dispensed into an Eppendorf UVette and 15 μ L of the appropriate metal stock was added. Solution absorbances were used to calculate concentrations of apo- and metalated forms of the relevant ligand. These concentrations were plotted against metal concentrations and fitted in DynaFit⁸⁷ using binding models as described in the text. The known association or dissociation constants for all competitor ligands are listed in Dataset S1d:

Overexpression and purification of AdcAI and AdcAII. Nucleic acid sequences encoding the soluble domains of AdcAI (from Thr21) and AdcAII (from Thr31) from M1GAS strain 5448 were subcloned into vector pSAT1-LIC using primers listed in Dataset S1c. This vector generates N-terminal His6-SUMO fusions with the target ORF. The resulting plasmids were propagated in *E. coli* Dh5 α , confirmed by Sanger sequencing, and transformed into *E. coli* BL21 Rosetta 2(DE3).

To express the proteins, transformants were plated onto LB agar. Fresh colonies were used to inoculate LB (1 L in 2 L baffled flasks) to an OD_{600} of 0.01. The culture media contained ampicillin (100 μ g/mL) and chloramphenicol (33 μ g/mL) as required. Cultures were shaken (200 rpm, 37 °C) until an OD_{600} of 0.6–0.8 was reached, and expression was induced by adding IPTG (0.1 mM). After shaking for a further 16 h at 20 °C, the cultures were centrifuged (4000 $\times$ g, 4 °C) and the pellets were resuspended in buffer A500 (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 5 mM imidazole, 10% glycerol).

To purify proteins, bacteria were lysed by sonication (40 kpsi), centrifuged (20,000 $\times$ g, 4 °C), and filtered through a 0.46 μ m PES membrane filtration unit. Clarified lysates were loaded onto a HisTrap HP column (Cytiva). The column was washed with 10 column volumes (CV) of buffer A500 followed by 10 CV of buffer A100 (20 mM Tris-HCl, pH 7.9, 100 mM NaCl, 10% w/v glycerol) containing imidazole (5 mM). Both AdcAI and AdcAII were bound to the column and subsequently eluted with 3 CV of buffer A100 containing 250 mM imidazole followed by 5 CV of 500 mM imidazole.

Protein-containing fractions were loaded onto a Q HP column (Cytiva). The column was washed with 5 CV of buffer A100 and bound proteins were eluted using a step gradient of 0, 10, 15, and 20% buffer C1000 (20 mM Tris-HCl, pH 7.9, 1000 mM NaCl, 10% w/v glycerol). Eluted proteins were incubated overnight at 4 °C with hSEN2 SUMO protease to cleave the His6-SUMO tag from the target protein. Samples were passed through a second Q HP column and the flowthrough fractions containing untagged target protein were collected.

AUTHOR CONTRIBUTIONS

KD conceived the project with input from NJ, SC. JH, KD, LS, NJ designed experiments. NJ provided oral streptococci strains. IH, SC, YS synthesised peptides for preliminary studies. IH, JH, KD, LS examined the effects of peptides on bacterial growth. JB, KD measured gene expression by qRT-PCR. KD, LS measured metal levels by ICP MS. IH, JH, SF measured affinities of peptides to Cu and Zn. JH produced AdcA and AdcAll proteins, and measured their affinities to Zn. LS examined the effects of peptides on bacterial survival. JH, KD, LS prepared figures and drafted the manuscript.

ACKNOWLEDGEMENT

This work was funded by the Wellcome Trust grant number 214930/Z/18/Z. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. This project was also supported by a Flexible Funding Award from the Durham Biophysical Sciences Institute. SF and JB were supported by studentships from the BBSRC Newcastle-Liverpool-Durham Doctoral Training Partnership.

T Blower (Durham University) provided constructs and reagents for production of AdcAI and AdcAll. GAS $\Delta adcAI$ and $\Delta czcD$ mutant strains were from C Ong, A McEwan, and M Walker (The University of Queensland). Quin2 was from T Young (Durham University). We thank R Borthwick and P Chivers (Durham University), and Y Ahmed and J Quinn (Newcastle University Biosciences Institute) for insightful discussions.

REFERENCES

- (1) Zhang, L. J.; Gallo, R. L. Antimicrobial peptides. *Curr Biol* **2016**, 26 (1), R14.
- (2) Kim, S. Y.; Zhang, F.; Gong, W.; Chen, K.; Xia, K.; Liu, F.; Gross, R.; Wang, J. M.; Linhardt, R. J.; Cotten, M. L. Copper regulates the interactions of antimicrobial piscidin peptides from fish mast cells with formyl peptide receptors and heparin. *J Biol Chem* **2018**, 293 (40), 15381.
- (3) Portelinha, J.; Heilemann, K.; Jin, J.; Angeles-Boza, A. M. Unraveling the implications of multiple histidine residues in the potent antimicrobial peptide Gaduscidin-1. *J Inorg Biochem* **2021**, 219, 111391.
- (4) Juliano, S. A.; Pierce, S.; deMayo, J. A.; Balunas, M. J.; Angeles-Boza, A. M. Exploration of the Innate Immune System of *Styela clava*: Zn(2+) Binding Enhances the Antimicrobial Activity of the Tunicate Peptide Clavanin A. *Biochemistry* **2017**, 56 (10), 1403.
- (5) Troxler, R. F.; Offner, G. D.; Xu, T.; Vanderspek, J. C.; Oppenheim, F. G. Structural relationship between human salivary histatins. *J Dent Res* **1990**, 69 (1), 2.

- 609 (6) Sabatini, L. M.; Azen, E. A. Histatins, a family of salivary histidine-rich proteins, are encoded
610 by at least two loci (HIS1 and HIS2). *Biochem Biophys Res Commun* **1989**, 160 (2), 495.
- 611 (7) Azen, E. A.; Leutenegger, W.; Peters, E. H. Evolutionary and dietary aspects of salivary basic
612 (Pb) and post Pb (PPb) proteins in anthropod primates. *Nature* **1978**, 273 (5665), 775.
- 613 (8) Helmerhorst, E. J.; Alagl, A. S.; Siqueira, W. L.; Oppenheim, F. G. Oral fluid proteolytic effects
614 on histatin 5 structure and function. *Arch Oral Biol* **2006**, 51 (12), 1061.
- 615 (9) Campese, M.; Sun, X.; Bosch, J. A.; Oppenheim, F. G.; Helmerhorst, E. J. Concentration and
616 fate of histatins and acidic proline-rich proteins in the oral environment. *Arch Oral Biol* **2009**,
617 54 (4), 345.
- 618 (10) Puri, S.; Edgerton, M. How does it kill?: understanding the candidacidal mechanism of
619 salivary histatin 5. *Eukaryot Cell* **2014**, 13 (8), 958.
- 620 (11) Du, H.; Puri, S.; McCall, A.; Norris, H. L.; Russo, T.; Edgerton, M. Human Salivary Protein
621 Histatin 5 Has Potent Bactericidal Activity against ESKAPE Pathogens. *Front Cell Infect*
622 *Microbiol* **2017**, 7, 41.
- 623 (12) Mochon, A. B.; Liu, H. The antimicrobial peptide histatin-5 causes a spatially restricted
624 disruption on the Candida albicans surface, allowing rapid entry of the peptide into the
625 cytoplasm. *PLoS Pathog* **2008**, 4 (10), e1000190.
- 626 (13) Helmerhorst, E. J.; Breeuwer, P.; van 't Hof, W.; Walgreen-Weterings, E.; Oomen, L. C. J. M.;
627 Veerman, E. C. I.; Nieuw Amerongen, A. V.; Abee, T. The cellular target of histatin 5 on
628 Candida albicans is the energized mitochondrion. *The Journal of Biological Chemistry* **1999**,
629 274 (March 12).
- 630 (14) Helmerhorst, E. J.; van 't Hof, W.; Veerman, E. C. I.; Simoons-Smit, I.; Nieuw Amerongen, A.
631 V. Synthetic histatin analogues with broad-spectrum antimicrobial activity. *Biochem J* **1997**,
632 326, 39.
- 633 (15) Norris, H. L.; Kumar, R.; Ong, C. Y.; Xu, D.; Edgerton, M. Zinc Binding by Histatin 5 Promotes
634 Fungicidal Membrane Disruption in C. albicans and C. glabrata. *J Fungi (Basel)* **2020**, 6 (3).
- 635 (16) Puri, S.; Li, R.; Ruszaj, D.; Tati, S.; Edgerton, M. Iron binding modulates candidacidal
636 properties of salivary histatin 5. *J Dent Res* **2015**, 94 (1), 201.
- 637 (17) Conklin, S. E.; Bridgman, E. C.; Su, Q.; Riggs-Gelasco, P.; Haas, K. L.; Franz, K. J. Specific
638 Histidine Residues Confer Histatin Peptides with Copper-Dependent Activity against Candida
639 albicans. *Biochemistry* **2017**, 56 (32), 4244.
- 640 (18) Hood, M. I.; Skaar, E. P. Nutritional immunity: transition metals at the pathogen-host interface.
641 *Nat Rev Microbiol* **2012**, 10 (8), 525.
- 642 (19) Turner, A. G.; Ong, C. Y.; Walker, M. J.; Djoko, K. Y.; McEwan, A. G. Transition Metal
643 Homeostasis in Streptococcus pyogenes and Streptococcus pneumoniae. *Adv Microb Physiol*
644 **2017**, 70, 123.
- 645 (20) Stewart, L. J.; Ong, C. L.; Zhang, M. M.; Brouwer, S.; McIntyre, L.; Davies, M. R.; Walker, M.
646 J.; McEwan, A. G.; Waldron, K. J.; Djoko, K. Y. Role of Glutathione in Buffering Excess
647 Intracellular Copper in *Streptococcus pyogenes*. *mBio* **2020**, 11 (6), e02804.

- 648 (21) Li, X. S.; Sun, J. N.; Okamoto-Shibayama, K.; Edgerton, M. Candida albicans cell wall ssa
649 proteins bind and facilitate import of salivary histatin 5 required for toxicity. *J Biol Chem* **2006**,
650 *281* (32), 22453.
- 651 (22) Jang, W. S.; Li, X. S.; Sun, J. N.; Edgerton, M. The P-113 fragment of histatin 5 requires a
652 specific peptide sequence for intracellular translocation in Candida albicans, which is
653 independent of cell wall binding. *Antimicrob Agents Chemother* **2008**, *52* (2), 497.
- 654 (23) Yu, H. Y.; Tu, C. H.; Yip, B. S.; Chen, H. L.; Cheng, H. T.; Huang, K. C.; Lo, H. J.; Cheng, J.
655 W. Easy strategy to increase salt resistance of antimicrobial peptides. *Antimicrob Agents*
656 *Chemother* **2011**, *55* (10), 4918.
- 657 (24) Han, J.; Jyoti, M. A.; Song, H. Y.; Jang, W. S. Antifungal Activity and Action Mechanism of
658 Histatin 5-Halocidin Hybrid Peptides against Candida ssp. *PLoS One* **2016**, *11* (2), e0150196.
- 659 (25) Helmerhorst, E. J.; Flora, B.; Troxler, R. F.; Oppenheim, F. G. Dialysis unmasks the fungicidal
660 properties of glandular salivary secretions. *Infect Immun* **2004**, *72* (5), 2703.
- 661 (26) Meurer, M.; O'Neil, D. A.; Lovie, E.; Simpson, L.; Torres, M. D. T.; de la Fuente-Nunez, C.;
662 Angeles-Boza, A. M.; Kleinsorgen, C.; Mercer, D. K.; von Kockritz-Blickwede, M. Antimicrobial
663 Susceptibility Testing of Antimicrobial Peptides Requires New and Standardized Testing
664 Structures. *ACS Infect Dis* **2021**, *7* (8), 2205.
- 665 (27) Fernandez-Presas, A. M.; Marquez Torres, Y.; Garcia Gonzalez, R.; Reyes Torres, A.; Becker
666 Fauser, I.; Rodriguez Barrera, H.; Ruiz Garcia, B.; Toloza Medina, R.; Delgado Dominguez,
667 J.; Molinari Soriano, J. L. Ultrastructural damage in Streptococcus mutans incubated with
668 saliva and histatin 5. *Arch Oral Biol* **2018**, *87*, 226.
- 669 (28) MacKay, B. J.; Denepitiya, L.; Iacono, V. J.; Krost, S. B.; Pollock, J. J. Growth-inhibitory and
670 bactericidal effects of human parotid salivary histidine-rich polypeptides on *Streptococcus*
671 *mutans*. *Infect Immun* **1984**, *44*, 695.
- 672 (29) Tian, X. L.; Salim, H.; Dong, G.; Parcels, M.; Li, Y. H. The BceABRS four-component system
673 that is essential for cell envelope stress response is involved in sensing and response to host
674 defence peptides and is required for the biofilm formation and fitness of Streptococcus
675 mutans. *J Med Microbiol* **2018**, *67* (6), 874.
- 676 (30) Andrian, E.; Qi, G.; Wang, J.; Halperin, S. A.; Lee, S. F. Role of surface proteins SspA and
677 SspB of Streptococcus gordonii in innate immunity. *Microbiology (Reading)* **2012**, *158* (Pt 8),
678 2099.
- 679 (31) Krzyściak, W.; Jurczak, A.; Piątkowski, J.; Kościelniak, D.; Gregorczyk-Maga, I.; Kołodziej, I.;
680 Papież, M. A.; Olczak-Kowalczyk, D. Effect of histatin-5 and lysozyme on the ability of
681 Streptococcus mutans to form biofilms in *in vitro* conditions. *Postepy Hig Med Dosw (online)*
682 **2015**, *69*, 1056.
- 683 (32) Helmerhorst, E. J.; Hodgson, R.; van 't Hof, W.; Veerman, E. C. I.; Nieuw Amerongen, A. V.
684 The Effects of Histatin-derived Basic Antimicrobial Peptides on Oral Biofilms. *J Dent Res*
685 **1999**, *78* (6), 1245.
- 686 (33) Greger, J. L.; Sickles, V. S. Saliva zinc levels: potential indicators of zinc status. *The*
687 *American Journal of Clinical Nutrition* **1979**, *32*, 1859.

- 688 (34) Sanson, M.; Makthal, N.; Flores, A. R.; Olsen, R. J.; Musser, J. M.; Kumaraswami, M.
689 Adhesin competence repressor (AdcR) from *Streptococcus pyogenes* controls adaptive
690 responses to zinc limitation and contributes to virulence. *Nucleic Acids Res* **2015**, *43* (1), 418.
- 691 (35) Ong, C. L.; Gillen, C. M.; Barnett, T. C.; Walker, M. J.; McEwan, A. G. An antimicrobial role for
692 zinc in innate immune defense against group A streptococcus. *J Infect Dis* **2014**, *209* (10),
693 1500.
- 694 (36) Young, C. A.; Gordon, L. D.; Fang, Z.; Holder, R. C.; Reid, S. D. Copper Tolerance and
695 Characterization of a Copper-Responsive Operon, *copYAZ*, in an M1T1 Clinical Strain of
696 *Streptococcus pyogenes*. *J Bacteriol* **2015**, *197* (15), 2580.
- 697 (37) Tedde, V.; Rosini, R.; Galeotti, C. L. Zn²⁺ Uptake in *Streptococcus pyogenes*:
698 Characterization of *adcA* and *Imb* Null Mutants. *PLoS One* **2016**, *11* (3), e0152835.
- 699 (38) Ong, C. L.; Berking, O.; Walker, M. J.; McEwan, A. G. New Insights into the Role of Zinc
700 Acquisition and Zinc Tolerance in Group A Streptococcal Infection. *Infect Immun* **2018**, *86* (6),
701 e00048.
- 702 (39) Grogan, J.; McKnight, C. J.; Troxler, R. F.; Oppenheim, F. G. Zinc and copper bind to unique
703 sites of histatin 5. *FEBS J* **2001**, *491*, 76.
- 704 (40) Melino, S.; Stefano Rufini, S.; Sette, M.; Morero, R.; Grottesi, A.; Paci, M.; Petruzzelli, R.
705 Zn(2+) ions Selectively Induce Antimicrobial Salivary Peptide Histatin-5 To Fuse Negatively
706 Charged Vesicles. Identification and Characterization of a Zinc-Binding Motif Present in the
707 Functional Domain. *Biochemistry* **1999**, *38*, 9626.
- 708 (41) Shetty, S. R.; Babu, S.; Kumari, S.; Shetty, P.; Hegde, S.; Karikal, A. Status of trace elements
709 in saliva of oral precancer and oral cancer patients. *J Cancer Res Ther* **2015**, *11* (1), 146.
- 710 (42) Duggal, M. S.; Chawla, H. S.; Curzon, M. E. J. A study of the relationship between trace
711 elements in saliva and dental caries in children. *Archives of Oral Biology* **1991**, *36* (12), 881.
- 712 (43) Inonu, E.; Hakki, S. S.; Kayis, S. A.; Nielsen, F. H. The Association Between Some Macro
713 and Trace Elements in Saliva and Periodontal Status. *Biol Trace Elem Res* **2020**, *197* (1), 35.
- 714 (44) Gusman, H.; Lendenmann, U.; Grogan, J.; Troxler, R. F.; Oppenheim, F. G. Is salivary
715 histatin 5 a metalloprotein? *Biochimica et Biophysica Acta* **2001**, *1545*, 86.
- 716 (45) Krezel, A.; Maret, W. The biological inorganic chemistry of zinc ions. *Arch Biochem Biophys*
717 **2016**, *611*, 3.
- 718 (46) Cao, K.; Li, N.; Wang, H.; Cao, X.; He, J.; Zhang, B.; He, Q. Y.; Zhang, G.; Sun, X. Two zinc-
719 binding domains in the transporter *AdcA* from *Streptococcus pyogenes* facilitate high-affinity
720 binding and fast transport of zinc. *J Biol Chem* **2018**, *293* (16), 6075.
- 721 (47) Young, T. R.; Xiao, Z. Principles and practice of determining metal-protein affinities. *Biochem*
722 *J* **2021**, *478* (5), 1085.
- 723 (48) Linke, C.; Caradoc-Davies, T. T.; Young, P. G.; Proft, T.; Baker, E. N. The laminin-binding
724 protein *Lbp* from *Streptococcus pyogenes* is a zinc receptor. *J Bacteriol* **2009**, *191* (18), 5814.
- 725 (49) Zupan, M. L.; Luo, Z.; Ganio, K.; Pederick, V. G.; Neville, S. L.; Deplazes, E.; Kobe, B.;
726 McDevitt, C. A. Conformation of the Solute-Binding Protein *AdcAll* Influences Zinc Uptake in
727 *Streptococcus pneumoniae*. *Front Cell Infect Microbiol* **2021**, *11*, 729981.

- 728 (50) Zimmermann, M.; Xiao, Z.; Cobbett, C. S.; Wedd, A. G. Metal specificities of Arabidopsis zinc
729 and copper transport proteins match the relative, but not the absolute, affinities of their N-
730 terminal domains. *Chem Commun (Camb)* **2009**, DOI:10.1039/b916472c
731 10.1039/b916472c(42), 6364.
- 732 (51) Doyle, C. M.; Naser, D.; Bauman, H. A.; Rumfeldt, J. A. O.; Meiering, E. M.
733 Spectrophotometric method for simultaneous measurement of zinc and copper in
734 metalloproteins using 4-(2-pyridylazo)resorcinol. *Anal Biochem* **2019**, *579*, 44.
- 735 (52) Rozga, M.; Sokolowska, M.; Protas, A. M.; Bal, W. Human serum albumin coordinates Cu(II)
736 at its N-terminal binding site with 1 pM affinity. *J Biol Inorg Chem* **2007**, *12* (6), 913.
- 737 (53) Young, T. R.; Wijekoon, C. J.; Spyrou, B.; Donnelly, P. S.; Wedd, A. G.; Xiao, Z. A set of
738 robust fluorescent peptide probes for quantification of Cu(ii) binding affinities in the
739 micromolar to femtomolar range. *Metallomics* **2015**, *7* (3), 567.
- 740 (54) Zhu, L.; Charbonneau, A. R. L.; Waller, A. S.; Olsen, R. J.; Beres, S. B.; Musser, J. M. Novel
741 Genes Required for the Fitness of Streptococcus pyogenes in Human Saliva. *mSphere* **2017**,
742 *2* (6), e00460.
- 743 (55) Brophy, M. B.; Hayden, J. A.; Nolan, E. M. Calcium ion gradients modulate the zinc affinity
744 and antibacterial activity of human calprotectin. *J Am Chem Soc* **2012**, *134* (43), 18089.
- 745 (56) Makthal, N.; Nguyen, K.; Do, H.; Gavagan, M.; Chandrangsu, P.; Helmann, J. D.; Olsen, R. J.;
746 Kumaraswami, M. A Critical Role of Zinc Importer AdcABC in Group A Streptococcus-Host
747 Interactions During Infection and Its Implications for Vaccine Development. *EBioMedicine*
748 **2017**, *21*, 131.
- 749 (57) Burcham, L. R.; Le Breton, Y.; Radin, J. N.; Spencer, B. L.; Deng, L.; Hiron, A.; Ransom, M.
750 R.; Mendonca, J. D. C.; Belew, A. T.; El-Sayed, N. M. et al. Identification of Zinc-Dependent
751 Mechanisms Used by Group B Streptococcus To Overcome Calprotectin-Mediated Stress.
752 *mBio* **2020**, *11* (6).
- 753 (58) Hartman, M. L.; Groppo, F.; Ohnishi, M.; Goodson, J. M.; Hasturk, H.; Tavares, M.; Yaskell,
754 T.; Floros, C.; Behbehani, K.; Razzaque, M. S. Can salivary phosphate levels be an early
755 biomarker to monitor the evolvement of obesity? *Contrib Nephrol* **2013**, *180*, 138.
- 756 (59) Savica, V.; Calo, L. A.; Caldarera, R.; Cavaleri, A.; Granata, A.; Santoro, D.; Savica, R.;
757 Muraca, U.; Mallamace, A.; Bellinghieri, G. Phosphate salivary secretion in hemodialysis
758 patients: implications for the treatment of hyperphosphatemia. *Nephron Physiol* **2007**, *105* (3),
759 p52.
- 760 (60) Lynge Pedersen, A. M.; Belstrom, D. The role of natural salivary defences in maintaining a
761 healthy oral microbiota. *J Dent* **2019**, *80 Suppl 1*, S3.
- 762 (61) Powell, K. J.; Brown, P. L.; Byrne, R. H.; Gajda, T.; Hefter, G.; Sjoberg, S.; Wanner, H.
763 Chemical speciation of environmentally significant metals with inorganic ligands - Part 2: The
764 Cu²⁺-OH⁻, Cl⁻, CO₃²⁻, SO₄²⁻, and PO₄³⁻ systems - (IUPAC technical report). *Pure Appl*
765 *Chem* **2007**, *79* (5), 895.

- 766 (62) Besold, A. N.; Gilston, B. A.; Radin, J. N.; Ramsoomair, C.; Culbertson, E. M.; Li, C. X.;
767 Cormack, B. P.; Chazin, W. J.; Kehl-Fie, T. E.; Culotta, V. C. Role of Calprotectin in
768 Withholding Zinc and Copper from *Candida albicans*. *Infect Immun* **2018**, 86 (2).
- 769 (63) Silva, F. D.; Rezende, C. A.; Rossi, D. C.; Esteves, E.; Dyszy, F. H.; Schreier, S.; Gueiros-
770 Filho, F.; Campos, C. B.; Pires, J. R.; Daffre, S. Structure and mode of action of microplusin,
771 a copper II-chelating antimicrobial peptide from the cattle tick *Rhipicephalus (Boophilus)*
772 *microplus*. *J Biol Chem* **2009**, 284 (50), 34735.
- 773 (64) Silva, F. D.; Rossi, D. C.; Martinez, L. R.; Frases, S.; Fonseca, F. L.; Campos, C. B.;
774 Rodrigues, M. L.; Nosanchuk, J. D.; Daffre, S. Effects of microplusin, a copper-chelating
775 antimicrobial peptide, against *Cryptococcus neoformans*. *FEMS Microbiol Lett* **2011**, 324 (1),
776 64.
- 777 (65) Carapetis, J. R.; Steer, A. C.; Mulholland, E. K.; Weber, M. The global burden of group A
778 streptococcal diseases. *Lancet Infect Dis* **2005**, 5 (11), 685.
- 779 (66) Shaikh, N.; Leonard, E.; Martin, J. M. Prevalence of streptococcal pharyngitis and
780 streptococcal carriage in children: a meta-analysis. *Pediatrics* **2010**, 126 (3), e557.
- 781 (67) Hamburger, M.; Robertson, O. H. Expulsion of group a hemolytic streptococci in droplets and
782 droplet nuclei by sneezing, coughing and talking. *The American Journal of Medicine* **1948**, 4
783 (5), 690.
- 784 (68) Hamburger Jr, M. Studies on the transmission of hemolytic streptococcus infections: II. Beta
785 hemolytic streptococci in the saliva of persons with positive throat cultures. *The Journal of*
786 *Infectious Diseases* **1944**, 71.
- 787 (69) Courtney, H. S.; Hasty, D. L. Aggregation of group A streptococci by human saliva and effect
788 of saliva on streptococcal adherence to host cells. *Infect Immun* **1991**, 59 (5), 1661.
- 789 (70) Courtney, H.; Hasty, D. Aggregation of group A streptococci by human saliva and effect of
790 saliva on streptococcal adherence to host cells. *Infection and immunity* **1991**, 59 (5), 1661.
- 791 (71) Brouwer, S.; Barnett, T. C.; Rivera-Hernandez, T.; Rohde, M.; Walker, M. J. Streptococcus
792 pyogenes adhesion and colonization. *FEBS Letters* **2016**, 590 (21), 3739.
- 793 (72) Shelburne, S. A., 3rd; Sumby, P.; Sitkiewicz, I.; Granville, C.; DeLeo, F. R.; Musser, J. M.
794 Central role of a bacterial two-component gene regulatory system of previously unknown
795 function in pathogen persistence in human saliva. *Proc Natl Acad Sci U S A* **2005**, 102 (44),
796 16037.
- 797 (73) Bik, E. M.; Long, C. D.; Armitage, G. C.; Loomer, P.; Emerson, J.; Mongodin, E. F.; Nelson, K.
798 E.; Gill, S. R.; Fraser-Liggett, C. M.; Relman, D. A. Bacterial diversity in the oral cavity of 10
799 healthy individuals. *ISME J* **2010**, 4 (8), 962.
- 800 (74) Zaura, E.; Keijser, B. J.; Huse, S. M.; Crielaard, W. Defining the healthy "core microbiome" of
801 oral microbial communities. *BMC Microbiol* **2009**, 9, 259.
- 802 (75) Dewhirst, F. E.; Chen, T.; Izard, J.; Paster, B. J.; Tanner, A. C.; Yu, W. H.; Lakshmanan, A.;
803 Wade, W. G. The human oral microbiome. *J Bacteriol* **2010**, 192 (19), 5002.
- 804 (76) Aas, J. A.; Paster, B. J.; Stokes, L. N.; Olsen, I.; Dewhirst, F. E. Defining the normal bacterial
805 flora of the oral cavity. *J Clin Microbiol* **2005**, 43 (11), 5721.

- (77) Bach, L. L.; Ram, A.; Ijaz, U. Z.; Evans, T. J.; Lindström, J. A Longitudinal Study of the Human Oropharynx Microbiota Over Time Reveals a Common Core and Significant Variations With Self-Reported Disease. *Frontiers in Microbiology* **2021**, *11* (3545).
- (78) Bochenska, O.; Rapala-Kozik, M.; Wolak, N.; Aoki, W.; Ueda, M.; Kozik, A. The action of ten secreted aspartic proteases of pathogenic yeast *Candida albicans* on major human salivary antimicrobial peptide, histatin 5. *Acta Biochim Pol* **2016**, *63* (3), 403.
- (79) Ikononova, S. P.; Moghaddam-Taaheri, P.; Wang, Y.; Doolin, M. T.; Stroka, K. M.; Hube, B.; Karlsson, A. J. Effects of histatin 5 modifications on antifungal activity and kinetics of proteolysis. *Protein Sci* **2020**, *29* (2), 480.
- (80) Hardt, M.; Thomas, L. R.; Dixon, S. E.; Newport, G.; Agabian, N.; Prakobphol, A.; Hall, S. C.; Witkowska, H. E.; Susan J. Fisher, S. J. Toward Defining the Human Parotid Gland Salivary Proteome and Peptidome. *Biochemistry* **2005**, *44* (8), 2885.
- (81) Vitorino, R.; Barros, A.; Caseiro, A.; Domingues, P.; Duarte, J.; Amado, F. Towards defining the whole salivary peptidome. *PROTEOMICS - Clinical Applications* **2009**, *3* (5), 528.
- (82) Gonzalez, P.; Bossak, K.; Stefaniak, E.; Hureau, C.; Raibaut, L.; Bal, W.; Faller, P. N-Terminal Cu-Binding Motifs (Xxx-Zzz-His, Xxx-His) and Their Derivatives: Chemistry, Biology and Medicinal Applications. *Chemistry* **2018**, *24* (32), 8029.
- (83) Herman, M.; Golasik, M.; Piekoszewski, W.; Walas, S.; Napierala, M.; Wyganowska-Swiatkowska, M.; Kurhanska-Flisykowska, A.; Wozniak, A.; Florek, E. Essential and Toxic Metals in Oral Fluid-a Potential Role in the Diagnosis of Periodontal Diseases. *Biol Trace Elem Res* **2016**, *173* (2), 275.
- (84) Manea, A.; Nechifor, M. Research on Plasma and Saliva Levels of Some Bivalent Cations in Patients with Chronic Periodontitis (Salivary Cations in Chronic Periodontitis) *Rev. Med. Chir. Soc. Med. Nat., Iași* **2014**, *118* (2), 439.
- (85) Romano, F.; Castiblanco, A.; Spadotto, F.; Di Scipio, F.; Malandrino, M.; Berta, G. N.; Aimetti, M. ICP-Mass-Spectrometry Ionic Profile of Whole Saliva in Patients with Untreated and Treated Periodontitis. *Biomedicines* **2020**, *8* (9).
- (86) Ramakers, C.; Ruijter, J. M.; Deprez, R. H.; Moorman, A. F. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. *Neurosci Lett* **2003**, *339* (1), 62.
- (87) Kuzmic, P. DynaFit--a software package for enzymology. *Methods Enzymol* **2009**, *467*, 247.